Actin-like Protein 6A Expression Correlates with Cancer Stem Cell-like Features and Poor Prognosis in Ovarian Cancer.

Abstract

Ovarian cancer has the highest mortality rate among gynecological cancers, often diagnosed at the late stage and lacking an effective targeted therapy. Although the study of malignant features of cancer, considered to be cancer stem cells (CSCs), is emerging, the aim of this study was to predict and explore the possible mechanism and clinical value of genetic markers in the development of ovarian cancer from a combined database with CSCs features. The common differentially expressed genes (DEGs) were selected in GSE185833 and GSE176246 datasets from the Gene Expression Omnibus (GEO). The GSE185833 dataset was created to reveal gene expression profiles of peritoneal metastasis tissues using single-cell sequencing, and the GSE176246 dataset was determined from gene expression profiles of chemotherapy-refractory ovarian cancer cell lines compared with ovarian cancer cell lines by RNA-seq analysis. By analyzing the correlation between common DEGs and prognosis of ovarian cancer and its possible pathways and functions were predicted by The Cancer Genome Atlas (TCGA) database. The expression levels of 11 genetic markers were significantly elevated in highly invasive and chemoresistant ovarian cancer. The expression of Actin-like protein 6A (ACTL6A) was found to be correlated with survival prognosis, and the total survival time of the patients with high expression of ACTL6A was shorter than those with low expression. Gene set enrichment analysis (GSEA) showed that ACTL6A positively enriched the gene set of 'Cell cycle' and ACTL6A negatively enriched the gene set of focal adhesion. CP724714, a human epidermal growth factor receptor 2 (HER2) inhibitor, could serve as a therapeutic option when ACTL6A levels are high in ovarian cancer cells. The high expression of ACTL6A is a poor prognostic factor in ovarian cancer and may serve as an effective biomarker for predicting treatment-refractory, metastasis, and prognosis of patients with ovarian cancer. The use of HER2 inhibitors is a promising therapeutic strategy against chemoresistant ovarian cancer.

• Authors: Po-Ming Chen, Chui-Nguk Wong, Chui-Na Wong, Pei-Yi Chu
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 24 Issue 3 (Jan 19 2023) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 36768349 (Publication Type: Journal Article)

Chemical References

• Actins
• ACTL6A protein, human
• Chromosomal Proteins, Non-Histone
• DNA-Binding Proteins
• Genetic Markers
• Transcription Factors

Topics

• Female
• Humans
• Actins (metabolism)
• Chromosomal Proteins, Non-Histone (metabolism)
• DNA-Binding Proteins (metabolism)
• Genetic Markers
• Neoplastic Stem Cells (metabolism)
• Ovarian Neoplasms (metabolism)
• Transcription Factors (genetics)
• Prognosis